Table 3 Mean values (CI) for EORTC QLQ-C30 scores before treatment (baseline) and follow-up and p-values and effect sizes for changes at follow-up compared to baseline

85.1 (81.5–88.7)

81.7 (78.1–85.3)

81.4 (77.4–85.4)

84.2 (80.5–87.9)

85.6 (81.7–89.5)

88.5 (85.2–91.9)

.006/0.32

.001/0.35

.038/0.25

ns/0.18

ns/0.04

77.8 (71.8–83.8)

65.4 ^§ (58.7–72.2)

74.1 (67.3–81.0)

80.7 (74.7–86.6)

85.4 (79.7–91.0)

89.2^§ 1 (84.5–93.9)

0.000/0.41

0.011/0.25

ns/0.08

ns/0.06

ns/0.19

86.9 (82.6–91.2)

80.5 (75.7–85.4)

83.5 (78.3–88.8)

87.2 (82.7–91.8)

88.0 (82.5–93.5)

90.1 (85.5–94.8)

.005/0.26

ns/0.16

ns/0.09

ns/0.07

ns/0.07

74.4 (69.7–79.1)

76.5 (71.9–81.1)

81.7 (77.7–85.6)

84.6^§ (80.6–88.6)

83.4 (78.0–88.8)

89.5^§ (85.7–93.2)

ns/0.09

.042/0.26

.002/0.37

.009/0.33

.000/0.61

83.5 (79.5–87.5)

84.0 (80.3–87.7)

87.8 (84.3–91.3)

88.1 (84.4–91.7)

87.6 (83.7–91.5)

88.3 (84.8–91.7)

ns/0.02

ns/0.15

ns/0.16

ns/0.12

ns/0.19

68.4 (64.1–72.6)

63.5 (59.1–67.9)

69.2 (64.7–73.7)

72.7 (68.4–77.1)

75.1 (69.9–80.3)

77.9 (73.0–82.9)

.015/0.24

ns/0.06

ns/0.08

ns/0.13

.007/0.31

17.7 (12.7–22.7)

35.4^§ (29.8–41.1)

23.5 (18.0–28.9)

17.7 (12.7–22.7)

14.9 (9.2–20.6)

8.7 (4.7–12.7)

.000/0.67

.002/0.35

ns/0.13

ns/0.04

ns/0.04

25.1 (20.6–29.7)

39.3^§ (34.1–44.5)

34.6 (29.1–40.2)

30.3 (25.3–35.3)

21.2 (16.3–26.1)

18.2 (13.6–22.7)

.000/0.63

.000/0.52

.000/0.41

ns/0.00

ns/0.16

5.2 (2.9–7.4)

14.2 (9.7–18.8)

12.0 (8.0–16.0)

7.0 (3.2–10.8)

2.7 (1.0–4.3)

1.4 (0.3–2.5)

.000/0.40

.000/0.42

ns/0.19

ns/0.05

ns/0.19